Last reviewed · How we verify
Avatrombopag Oral Tablet
Avatrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes.
Avatrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes. Used for Thrombocytopenia in patients with chronic liver disease undergoing invasive procedures, Chronic immune thrombocytopenia (ITP).
At a glance
| Generic name | Avatrombopag Oral Tablet |
|---|---|
| Also known as | Doptelet |
| Sponsor | Sobi, Inc. |
| Drug class | Thrombopoietin receptor agonist |
| Target | TPO receptor (c-Mpl) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Avatrombopag mimics the action of endogenous thrombopoietin, a cytokine that regulates platelet production. By activating the TPO receptor (also called c-Mpl) on megakaryocyte progenitor cells, it promotes their proliferation and differentiation, leading to increased platelet output from the bone marrow. This mechanism is used to treat thrombocytopenia (low platelet counts) in patients with chronic liver disease undergoing invasive procedures or in patients with immune thrombocytopenia.
Approved indications
- Thrombocytopenia in patients with chronic liver disease undergoing invasive procedures
- Chronic immune thrombocytopenia (ITP)
Common side effects
- Headache
- Nausea
- Diarrhea
- Abdominal pain
- Fatigue
Key clinical trials
- Avatrombopag vs. Placebo for CIT in GI Malignancies (PHASE2)
- Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months (PHASE3)
- Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP (PHASE3)
- The Holistic Study (PHASE3)
- Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study (PHASE4)
- Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim (PHASE4)
- Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers (PHASE3)
- Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avatrombopag Oral Tablet CI brief — competitive landscape report
- Avatrombopag Oral Tablet updates RSS · CI watch RSS
- Sobi, Inc. portfolio CI